Alpha Tau Medical Ltd.
NASDAQ:DRTSBiotechnology
+$0.04 today
- Market cap
- $1.11B
- Beta
- 1.20
- P/E (TTM)
- -15.2
- EPS (TTM)
- -$0.63
Volume 0.64M
Average 0.69M
DRTS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Alpha Tau Medical Ltd.NASDAQ: DRTS
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 89.71M shares rose 27.3% year over year, ahead of the +21.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 4.7% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +27.3% holds above the trailing-twelve-month pace of +21.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 80.58M USD
- Year-over-year change
- +15.2%
- 4-year CAGR
- +18.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.58M | +15.2% |
| FY2024 | 2024-12-31 | 69.93M | +0.8% |
| FY2023 | 2023-12-31 | 69.38M | +9.2% |
| FY2022 | 2022-12-31 | 63.53M | +56.8% |
| FY2021 | 2021-12-31 | 40.53M | — |
Weighted Avg Shares (Diluted) vs competitors
How DRTS compares with its peers on the latest reported figures
- DRTS's LTM Mar 2026 weighted avg shares (diluted) of 85.25M shares is the highest of the 3 companies compared; the peer median is 53.74M shares.
- Its year-over-year change of +21.6% is the 2nd highest of 3, against a peer median of +14.5%.
- Over three fiscal years its annual growth of +8.2% compares with a peer median of +12.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 85.25M | +21.6% | +8.2% | |
| LTM Mar 2026 | 54.95M | -21.6% | +10.4% | |
| FY2025 | 52.52M | +50.6% | +14.6% | |
| Peer median (excluding DRTS) | 53.74M | +14.5% | +12.5% | |
Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 776K | 979K | 1.07M | 1.1M | 1.23M |
| Gross Profit | (776K) | (979K) | (1.07M) | (1.1M) | (1.23M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.45M | 20.89M | 26.42M | 27.02M | 30.83M |
| Selling, General & Admin | 2.34M | 11.25M | 9.26M | 7.92M | 10.22M |
| Operating Expenses | 13.79M | 32.14M | 34.61M | 34.94M | 41.06M |
| Depreciation & Amortization | 776K | 979K | 1.07M | 1.1M | 1.23M |
| EBITDA | (13.22M) | (32.74M) | (28.03M) | (30.3M) | (41.06M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.79M) | (32.14M) | 35.68M | (36.04M) | (42.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 211K | 1.79M | 4.76M | 4.28M | 3.84M |
| Interest Expense | 13.27M | 1.77M | 39K | 344K | 419K |
| Other Income / Expenses | (13.47M) | (1.61M) | 6.54M | 4.3M | (218K) |
| Income Before Tax | (27.26M) | (33.74M) | (29.14M) | (31.74M) | (42.51M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 7K | 20K | 16K | 6K | 121K |
| Net Income | (27.27M) | (33.76M) | (29.16M) | (31.75M) | (42.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.67) | (0.53) | (0.42) | (0.45) | (0.53) |
| EPS (Diluted) | (0.67) | (0.53) | (0.42) | (0.45) | (0.53) |
| Weighted Avg Shares | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
| Weighted Avg Shares (Diluted) | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
Alpha Tau Medical Ltd.
NASDAQ:DRTS
Intrinsic Alpha fair value
Locked
Current Price
$12.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.